InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (10 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
10
T+90 hit rate
33%
T+90 mean return
-4.6%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Burrows Scott L, Chief Financial Officer. Insider active across 2 companies, notably Arcutis Biotherapeutics, Inc.. Cumulatively, 16 reports have been recorded. Breakdown: 0 buy · 10 sells. Total volume traded: €921k. Activity tracked since 27 December 2021. The latest transaction was filed on 1 June 2026 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations16 total
10,000 sharesCommon StockSEC:0001853327-26-000008:2
15,000 sharesCommon StockSEC:0001853327-26-000008:0
5,000 sharesCommon StockSEC:0001853327-26-000008:1
7,500 shares@ US$14.5016.9% of flowCommon StockSEC:0001636282-26-000076:0
1,801 shares@ US$69.7519.6% of flowCommon StockSEC:0001636282-26-000076:1
2,599 shares@ US$70.7728.7% of flowCommon StockSEC:0001636282-26-000076:2
3,100 shares@ US$72.0634.8% of flowCommon StockSEC:0001636282-26-000076:3
134,953 shares0Common StockSEC:0000950170-23-072763:0
291 shares@ US$15.26340.9% of flowCommon StockSEC:0001567619-23-004671:0
21,000 shares0Common StockSEC:0001567619-23-004547:0
416 shares@ US$16.16631.3% of flowCommon StockSEC:0001567619-23-004270:0
5,000 shares@ US$1.68061.8% of flowCommon StockSEC:0001567619-22-017633:0
13,300 shares0Common StockSEC:0001567619-22-006494:0
420 shares@ US$17.75270.0002% mcap1.5% of flowCommon StockSEC:0001567619-22-006228:0
12,560 shares@ US$20.07480.0083% mcap49.3% of flowCommon StockSEC:0000899243-21-049940:0
12,560 shares@ US$20.074847.3% of flowCommon StockSEC:0000899243-21-049940
16 of 16 declarations
About Burrows Scott L
Scott L. Burrows is the Chief Financial Officer of Arcutis Biotherapeutics, Inc. He is responsible for the financial management of the company, including budgeting and financial strategy, to support the company's research and development goals.
